Heart failure & cardiomyopathiesCohort study
COVID-19 outcomes and persistent symptoms in patients with hypertrophic cardiomyopathy: association with pre-existing cardiovascular magnetic resonance phenotype
- international hypertrophic cardiomyopathy (HCM) Registry
- patient-reported questionnaires
- multivariable logistic regression
Authors' conclusion
In this large HCM cohort, COVID-19 was associated with a substantial burden of persistent symptoms, but pre-existing CMR phenotype was not associated with adverse outcomes. These findings suggest that baseline structural disease severity may not identify patients at higher risk of post-COVID-19 complications, although results should be interpreted in the context of self-reported outcomes and limited event rates.
Study context
- Population
- Participants from the international HCM Registry with prior cardiovascular magnetic resonance (CMR) phenotyping767 with reported COVID-19 infection
- Participants
- 1,704 participants
- Exposure
- Associations between baseline CMR features and hospitalisation or impaired recovery (≥3 months)
Main finding
As reported in the abstract
required hospitalisation
4%
reported impaired recovery at ≥3 months
19%
non-cardiac deaths
2 (0.26%)
Observational data: associations, not effects.
Further findings
Persistent symptoms
- fatigue
- 67%
- dyspnoea
- 33%
Association of adverse CMR features (hypertrophy, fibrosis (late gadolinium enhancement), extracellular volume) with hospitalisation or impaired recovery
- not associated with hospitalisation or impaired recovery
- After adjustment
Predictors of persistent symptoms
- Female sex and younger age were associated with persistent symptoms
Original publication
Summarised from the published abstract; every number is checked against it